Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Abivax began the double-blind, placebo-controlled, European Phase IIa ABX464-004 trial to evaluate 50 mg oral ABX464 once daily for 28 days with Prezista darunavir plus ritonavir or with Prezista plu...